Male balding is a major risk factor for severe COVID-19 - 10/10/20
Doi : 10.1016/j.jaad.2020.07.062
Justin Lee, BS a, Ahmed Yousaf, BA a, Wei Fang, PhD b, Michael S. Kolodney, MD, PhD a, ⁎ 
a Department of Dermatology, West Virginia University
b Virginia Clinical and Translational Science Institute, Morgantown, West Virginia
∗Reprint requests: Michael S. Kolodney, MD, PhD, PO Box 9158, School of Medicine, Department of Dermatology, Health Sciences Center, Morgantown, WV 26505-9158School of MedicineDepartment of DermatologyHealth Sciences CenterMorgantownWV26505-9158
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Graphical abstract |
| Authors Lee and Yousaf are co-first authors. |
|
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: UK Biobank received ethical approvals from the North West Multicenter Research Ethics Committee (MREC), which covers the UK, the Community Health Index Advisory Group (CHIAG) covering Scotland, the Patient Information Advisory Group (PIAG) for gaining access to invite people to participate and National Research Ethics Service. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. e353-e354 - novembre 2020 Retour au numéro
Article précédent
- Approaching the dermatology residency application process during a pandemic
- Ilana S. Rosman, Courtney R. Schadt, Sara S. Samimi, Misha Rosenbach
- Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
- Diego Fernandez-Nieto, David Saceda-Corralo, Juan Jimenez-Cauhe, Oscar Muñoz Moreno-Arrones, Rita Rodrigues-Barata, Angela Hermosa-Gelbard, Sergio Vano-Galvan
Bienvenue sur EM-consulte, la référence des professionnels de santé.